TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07326566: Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII

Sponsor: Black Diamond Therapeutics, Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 162 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,557,400

Rescue Site Savings

+$2,356,200

Unlock Full NCT07326566 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07326566 Rescue Dossier →